English Korean Chinese
ホーム > 市場調査レポート > 医薬品 > 感染症 > 世界の抗感染薬Vol.II:抗菌剤
カテゴリ
医薬品 (4964)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (181)
感染症 (353)
規制環境 (132)
後発医薬品 (135)
骨疾患 (37)
処方薬 (158)
神経疾患 (174)
精神疾患 (89)
製薬企業関連 (531)
創薬 (1524)
糖尿病 (193)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

世界の抗感染薬Vol.II:抗菌剤

Anti Infectives, Vol II: Antibacterials

発行 Kalorama Information
出版日 2007年04月 商品コード 50805
ページ情報 英文 276 Pages
価格
US$ 2,995 換算 ¥ 241,007 (税抜) PDF by E-mail (Single User License)
US$ 3,395 換算 ¥ 273,195 (税抜) Hard Copy
US$ 5,990 換算 ¥ 482,015 (税抜) PDF by E-mail (Global Site License)


原文目次

Abstract

Antibacterial drugs have turned bacterial infections into treatable ailments rather than the life-threatening conditions they once were. But the effectiveness of many antibiotics is being reduced as more and more types of bacteria become resistant to them. Because of antibiotic resitance and other changing dynamics, knowledge of issues and trends is necessary to operate the antibacterials market.

Kalorama' s Anti-Infectives, Vol. II: Antibacterials provides extensive detail on the anti-bacterial market, including the following critical trends:

  • Drug resistance and Interactions
  • Antibiotic Abuse
  • Antibiotic Cycling
  • Addressing Market Trends
  • Antibiotic Use in Agriculture
  • Antibiotic Education
  • Children and Bacterial Resistance
  • The Elderly and Bacterial Resistance
  • Compromised Individuals and Bacterial Resistance
  • Screening Hospital Patients
  • Side Effects of Antibiotics
  • Partnerships and Alliances
  • Environment and Drug Resistance
  • Methicillin Resistant Staphylococcus Aureus

In this, the second volume of Kalorama Information' s Anti-Infective Markets series, the antibacterial drug market is broken down into seven general categories based on drug class:

  • cephalosporins
  • macrolides
  • penicillins
  • quinolones
  • sulfonamides
  • tetracyclines
  • other misc. antibiotics

There is a significant trend shift occuring in the antibacterials market since Kalorama Information' s last edition in 2005. Anti-Infectives Vol. II: Antibacterials covers that shift in detail. For each marketplace segment, Market Size, Growth and Share are provided, and revenue is forecasted to 2011 are provided. Current products are discussed and new pipeline products are assessed. In total, over 100 Tables and Figures provide accessible data on this growing market, a depth of coverage unsurpassed by any competitive study.

The following companies are profiled as part of this report:

  • Abbott Laboratories
  • AstraZeneca
  • Bayer Schering Pharma
  • Cubist Pharmaceuticals
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Johnson & Johnson Group
  • King Pharmaceuticals
  • Merck & Company, Inc.
  • Pfizer, Inc.
  • Roche
  • Sanofi-Aventis
  • Wyeth

Table of Contents

Executive Summary

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

Introduction The World Market for Anti-Infectives Volume 2:

  • Antibacterial Drugs
  • Introduction to pathogens
    • Classification of Antibacterial Organisms
    • Antimicrobial Spectrum
    • Bacterial Resistance
    • Principles of Anti-infective Therapy
    • Infecting Organism
    • Antibiotic Sensitivity Testing
    • Site of Infection
    • Host Defenses and Organ Function
    • Antibiotic Pharmacokinetics
    • Monitoring Therapy
    • Combination Therapy and Prophylactic Use
  • Demographics and Statistics

Issues and Trends Affecting the Antibacterial Drug Market

  • introduction
  • Drug Resistance and Interactions
  • Antibiotic Abuse
  • Antibiotic Cycling
  • addressing market trends
  • Antibiotic use in Agriculture
  • Antibiotic Education
  • Children and Bacterial resistance
  • The Elderly and Bacterial Resistance
  • Compromised Individuals and Bacterial Resistance
  • Screening Hospitalized patients
  • Side Effects of Antibiotics
  • Partnerships and Alliances
  • Environment and Drug Resistance
  • Methicillin-resistant Staphylococcus Aureus (MRSA)

Cephalosporin Antibiotics

  • Overview
  • Description of Products
    • First Generation Cephalosporins
    • Cephalexin (Keflex, Advancis Pharmaceuticals)
    • Cefazolin (Ancef, GlaxoSmithKline; Cefamezin, Astellas)
    • Cefadroxil (Duricef, Bristol-Myers Squibb/Warner Chilcot)
    • Second Generation Cephalosporins
    • Cefuroxime (Ceftin, GlaxoSmithKline)
    • Cefoxitin (Mefoxin, Merck)
    • Third Generation Cephalosporins
    • Cefotaximen (Claforan offered by Sanofi-Aventis)
    • Cefoperazone (Cefobid, Pfizer)
    • Ceftibutin (Cedax, Shionogi)
    • Ceftizoxime (Cefizox, Astellas)
    • Ceftriaxone (Rocephin, Roche)
    • Ceftazidime (Fortaz, GlaxoSmithKline)
    • Cefixime (Suprax, Wyeth/Lupin Pharmaceuticals)
    • Cefpodoxime (Vantin, Pfizer)
    • Fourth Generation Cephalosporins
    • Cefepime (Maxipime, Bristol-Myers Squibb)
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Macrolide Antibiotics

  • Overview
  • Description of Products
    • Azithromycin (Zithromax, Pfizer; Zmax, Pfizer)
    • Clarithromycin (Biaxin, Abbott Laboratories)
    • Erythromycin (Erythrocin, Abbott Laboratories; EryPed, Abbott Laboratories)
    • Telithromycin (Ketek, Sanofi-Aventis)
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Penicillin Antibiotics

  • Overview
  • Natural Penicillins
  • Penicillinase-Resistant Penicillins
  • Broad -Spectrum Penicillins
  • Extended-Spectrum Penicillins

Description of Products

  • Natural Penicillins
  • Penicillin G (Bicillin, King Pharmaceuticals; Pfizerpen, Pfizer)
  • Penicillinase-resistant Penicillins
  • Cloxacillin (Cloxapen, GlaxoSmithKline)
  • Oxacillin (Bactocill, GlaxoSmithKline)
  • Broad-spectrum Penicillins
  • Amoxicillin (Augmentin, GlaxoSmithKline; Amoxil,GlaxoSmithKline)
  • Ampicillin (Unasyn, Pfizer)
  • Extended-spectrum Penicillins
  • Carbenicillin (Geocillin, Pfizer)
  • Piperacillin (Pipracil, Wyeth; Zosyn, Wyeth)
  • Ticarcillin (Timentin, GlaxoSmithKline)
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Quinolone Antibiotics

  • Overview
  • Description of Products
    • Ciprofloxacin (Cipro, Bayer; Proquin XR, Depomed)
    • Gemifloxacin (Factive, LG Chem Ltd. and Oscient Pharmaceuticals)
    • Lomefloxacin (Maxaquin, Unimed)
    • Nalidixic (NegGram, Sanofi-Aventis)
    • Norfloxacin (Noroxin, Merck)
    • Ofloxacin (Floxin, Ortho-McNeil)
    • Moxifloxicin (Avelox, Bayer; Vigamox, Alcon)
    • Levofloxacin (Levaquin, Ortho-McNeil; Tavanic, Sanofi-Aventis; Cravit, Daiichi Sankyo; Quixin, Santen)
    • Gatifloxacin (Zymar, Allergan/Kyorin)
    • Trovafloxacin (Trovan, Pfizer)
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Sulfonamide Antibiotics

  • Overview
  • Description of Products
  • Sulfisoxazole (Gantrisin Pediatric, Roche)
    • Oxytetracycline/Sulfamethizole/Phenazopyridine (Urobiotic, Pfizer)
    • Erythromycin ethylsuccinate and Sulfisoxazole acetyl (Pediazole, Ross)
    • Dapsone (Aczone Gel, QLT USA-Tolmar Inc.)
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Tetracycline Antibiotics

  • Overview
  • Description of Products
  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Other Miscellaneous Antibiotics

  • Overview
  • Description of Products
  • Aminoglycosides
    • Amikacin Sulfate (Amikin, Bristol-Myers Squibb)
    • Kanamycin Sulfate (Kantrex, Bristol-Myers Squibb)
    • Neomycin Sulfate (Neo-fradin, X Gen Pharms)
    • Streptomycin Sulfate (Streptomycin, Pfizer)
    • Lincomycin
    • Clindamycin (Cleocin, Pfizer; Clindesse, KV Pharmaceutical Company; Evoclin, Connetics Corp.; Ziana Gel, Medicis/Dow)
    • Chloramphenicol
    • Chloramphenicol (Chloromycetin,Pfizer)
    • Glycopeptide
    • Vancomycin (Vancocin, Viropharma)
    • Monobactams
    • Aztreonam (Azactam, Bristol-Myers Squibb)
    • Carbapenems
    • Imipenem/cilastatin (Primaxin, Merck)
    • Meropenem (Merrem, AstraZeneca)
    • Metronidazole
    • Metronidazole (Flagyl, Pfizer; Pylera, Axcan; Metrogel-Vaginal, 3M Pharmaceuticals; MetroGel, Galderma)
    • Antituberculars
    • Rifampicin (Rifater, Sanofi-Aventis)
    • Capreomycin (Capastat sulfate, Eli Lilly & Co.)
    • Ethionamide (Trecator SC, Wyeth)
    • Aminosalicylic acid granules (Paser Granules, Jacobus Pharmaceutical)
    • Cycloserine (Seromycin, Eli Lilly & Co.)
    • Antileprotics
    • Dapsone (Dapsone, Jacobus)
    • Oxazolidinones
    • Linezolid (Zyvox, Pfizer)
    • Ketolides
    • Telithromycin (Ketek, Sanofi-Aventis)
    • Lipopeptides
    • Daptomycin (Cubicin, Cubist Pharmaceutical)
    • Glycyclines
    • Tigecycline (Tygacil, Wyeth)
    • Generic Drug Impact and Availability
    • Research and Development
    • Market Size and Growth
    • Competitive Analysis

Corporate Profiles

  • Introduction
  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer Schering Pharma AG
  • Cubist Pharmaceuticals, Inc
  • Daiichi Sankyo Co., Ltd.
  • GlaxoSmithKline
  • Johnson & Johnson Group
  • King Pharmaceuticals, Inc.
  • Merck & Company, Inc.
  • Pfizer, Inc.
  • Roche
  • Sanofi-Aventis
  • Wyeth

Company Names and Addresses

Back to Top